Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. I. Requirement of Lyt-1 dull L3T4 bright normal T cells for the induction of thyroiditis. 1988

S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
Biomedical Center, Osaka University Medical School, Japan.

T cell-depleted C3H/He or (C57BL/6xC3H/He)F1 (B6C3F1) mice were prepared by adult thymectomy and injection of antithymocyte serum, followed 3 wk later by lethal x-irradiation and bone marrow reconstitution. When these T cell-depleted mice were not injected or injected i.v. with normal spleen and lymph node cells treated with either anti-Thy-1, -L3T4 or -Lyt-2 antibody plus C or C alone, none of the groups of mice developed thyroiditis. In contrast, the adoptive transfer of normal cells treated with anti-Lyt-1 plus C resulted in high incidence of the production of antithyroglobulin antibody and the induction of typical thyroiditis lesion. The thyroid was the sole organ involved, because neither typical inflammatory lesion in other organs nor autoantibody such as anti-DNA antibody was detected in mice that exhibited thyroiditis. Analyses of surface phenotypes of cells required for inducing thyroiditis by the adoptive transfer revealed that an appreciable percentage of Lyt-1 dull T cells remained after the treatment of normal lymphoid cells with anti-Lyt-1 plus C. Almost all of these Lyt-1 dull T cells expressed magnitudes of L3T4 or Lyt-2 Ag comparable to those detected on Lyt-1 bright T cells. More important, the induction of thyroiditis was almost completely prevented by either in vitro or in vivo elimination of Lyt-1 dull L3T4+(bright) but not of Lyt-1 dull Lyt-2+(bright) T cells. These results indicate that Lyt-1 dull L3T4+ T cells existing in normal healthy individuals have potential to induce typical thyroiditis which is associated with the production of antithyroglobulin autoantibody, and that the activation and/or function of this T cell subset is regulated by the Lyt-1 bright T cell population coexisting in normal lymphoid cell population.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005260 Female Females
D006377 T-Lymphocytes, Helper-Inducer Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions. Helper Cell,Helper Cells,Helper T Cell,Helper-Inducer T-Lymphocytes,Inducer Cell,Inducer Cells,T-Cells, Helper-Inducer,T-Lymphocytes, Helper,T-Lymphocytes, Inducer,Helper T-Cells,Cell, Helper T,Cells, Helper T,Helper Inducer T Lymphocytes,Helper T Cells,Helper T-Cell,Helper T-Lymphocyte,Helper T-Lymphocytes,Helper-Inducer T-Cell,Helper-Inducer T-Cells,Helper-Inducer T-Lymphocyte,Inducer T-Lymphocyte,Inducer T-Lymphocytes,T Cell, Helper,T Cells, Helper,T Cells, Helper Inducer,T Lymphocytes, Helper,T Lymphocytes, Helper Inducer,T Lymphocytes, Inducer,T-Cell, Helper,T-Cell, Helper-Inducer,T-Cells, Helper,T-Lymphocyte, Helper,T-Lymphocyte, Helper-Inducer,T-Lymphocyte, Inducer
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
January 1990, International immunology,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
January 1989, Regional immunology,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
January 1993, Journal of immunology (Baltimore, Md. : 1950),
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
November 1985, The Journal of experimental medicine,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
January 1989, Immunology letters,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
August 1986, Journal of immunology (Baltimore, Md. : 1950),
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
October 1987, The Journal of experimental medicine,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
September 1984, Cellular immunology,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
November 1976, Proceedings of the Royal Society of Medicine,
S Sugihara, and Y Izumi, and T Yoshioka, and H Yagi, and T Tsujimura, and O Tarutani, and Y Kohno, and S Murakami, and T Hamaoka, and H Fujiwara
September 2005, Cancer research,
Copied contents to your clipboard!